HCW9218 for Solid Tumors

Masonic Cancer Center - University of Minnesota, Minneapolis, MN
Solid TumorsHCW9218 - Drug
All Sexes

Study Summary

This trial is testing a new drug, HCW9218, to see if it is effective in treating advanced/metastatic solid tumor cancer. The drug is administered by injection and is a fusion protein complex that activates IL-15R signaling on effector immune cells.

Eligible Conditions
  • Solid Tumors

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1

Similar Trials

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 12 months after 1st dose

Year 1
Estimate progression free survival (PFS)
Estimate progression of overall survival (OS)
Month 12
Estimate response rate (complete response (CR), partial response (PR) or stable disease (SD)
Month 12
The primary objective of the dose finding component is to determine the maximum tolerated dose (MTD) of HCW9218

Trial Safety

Phase-Based Safety

1 of 3

Similar Trials

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

Administer HCW9218
1 of 1

Experimental Treatment

24 Total Participants · 1 Treatment Group

Primary Treatment: HCW9218 · No Placebo Group · Phase 1

Administer HCW9218
Experimental Group · 1 Intervention: HCW9218 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 12 months after 1st dose

Who is running the clinical trial?

Masonic Cancer Center, University of MinnesotaLead Sponsor
265 Previous Clinical Trials
15,998 Total Patients Enrolled
Melissa Geller, MDPrincipal InvestigatorMasonic Cancer Center, Univeristy of Minnesota
6 Previous Clinical Trials
234 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Has HCW9218 received clearance from the Food and Drug Administration?

"HCW9218 is classified as a Phase 1 trial, so our team at Power assigned it a score of 1 due to the sparse clinical data supporting safety and efficacy." - Anonymous Online Contributor

Unverified Answer

Are there any remaining slots available in this medical experiment?

"According to the details available on clinicaltrials.gov, this trial has been actively recruiting participants since it was posted on April 1st 2022 and last updated a little over two weeks later." - Anonymous Online Contributor

Unverified Answer

What is the aggregate figure of participants taking part in this experiment?

"Absolutely. Evident on clinicaltrials.gov, the medical trial was first announced on April 1st 2022 and was revised most recently in mid-April; The research team is currently recruiting 24 people from a single clinic for participation." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.